8 completed, 3 recruiting, 2 active not recruiting, 2 terminated. 8 Phase 3, 7 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 6, Recruiting 1, Terminated 1 |
| Phase 2 | 7 | Active not recruiting 2, Completed 2, Recruiting 2, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow CT-P6: new trials by email Literature Review of CT-P6 trials Research Report on CT-P6
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial Biospecimen Collection, Hormone Therapy, Pembrolizumab - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 120 | 2025-10-09 | 2026-11-03 |
| Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | Recruiting | NRG Oncology | 146 | 2023-03-03 | 2026-10-23 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer Copanlisib, Pertuzumab, Trastuzumab - Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2021-05-20 | 2025-10-01 |
| Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Atezolizumab, Biopsy, Bone Scan - Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Terminated | National Cancer Institute (NCI) | 190 | 2019-04-05 | 2026-05-29 |
| TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer Anastrozole, Denifanstat, Exemestane - Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma | Phase 2 | Completed | Mayo Clinic | 17 | 2017-08-03 | 2026-10-09 |
| Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2017-03-23 | 2026-07-30 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
| Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure - HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 315 | 2014-02-18 | 2026-10-06 |
| Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 203 | 2011-02-14 | 2026-06-02 |
| Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Cyclophosphamide, Docetaxel, Doxorubicin - HER2/Neu Positive, Progesterone Receptor Positive | Phase 3 | Completed | National Cancer Institute (NCI) | 3270 | 2011-02-08 | 2025-07-14 |
| Demonstrate Efficacy and Safety of Metastatic Breast Cancer CT-P6, Herceptin, Paclitaxel - Metastatic Breast Cancer | Phase 3 | Completed | Celltrion | 475 | 2010-06-01 | 2025-02-11 |
| Evaluate Safety, Efficacy and Pharmacokinetics CT-P6, Herceptin, Paclitaxel - Metastatic Breast Cancer | Phase 1 / Phase 2 | Completed | Celltrion | 143 | 2010-02-01 | 2025-01-24 |
| Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery Laboratory Biomarker Analysis, Lapatinib Ditosylate, Paclitaxel - Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7 | Phase 3 | Completed | National Cancer Institute (NCI) | 305 | 2009-02-24 | 2026-08-12 |
| Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Laboratory Biomarker Analysis, Trastuzumab, Whole Breast Irradiation - Breast Ductal Carcinoma In Situ | Phase 3 | Completed | National Cancer Institute (NCI) | 2014 | 2008-12-10 | 2025-06-12 |
Breast Neoplasms (8) · Esophageal Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Breast Neoplasms, Male (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Glioma (1) · Hematologic Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1) · Melanoma (1)
National Cancer Institute (NCI) (9) · Celltrion (2) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · NRG Oncology (1) · SWOG Cancer Research Network (1)
United States (13) · Puerto Rico (5) · Canada (3) · South Korea (3) · Guam (1) · Ireland (1)
Investigational Site (2) · Alan L Ho (1) · Charles E Geyer (1) · Howard P Safran (1) · Keith T Flaherty (1) · Lisa A Carey (1) · Louis Fehrenbacher (1) · Mariya Rozenblit (1) · Melody A Cobleigh (1) · Mothaffar F Rimawi (1) · Roisin M Connolly (1) · Senthilkumar Damodaran (1) · Tufia C. Haddad, M.D. (1) · Vicente Valero, MD (1)
PMID 23984897, PMID 26527775, PMID 26586415, PMID 31821109, PMID 32463741, PMID 33048619, PMID 33095682, PMID 33739848, PMID 35038433, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38433347, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40170372, PMID 40480221, PMID 40865033, PMID 41066729, PMID 41213241
U10CA180868 (6), U10CA012027 (3), U10CA180820 (2), P30CA016672 (1), U10CA021661 (1), U10CA031946 (1), U10CA180821 (1), U10CA180830 (1), U10CA180888 (1), U24CA196172 (1), UM1CA186688 (1)